60901-27-1

Usage

Uses

Used in Pharmaceutical Industry:
N-(4-chlorophenyl)ethanesulfonamide is used as an analgesic and anti-inflammatory agent for the treatment of various inflammatory conditions. It is effective in managing pain and inflammation associated with osteoarthritis, rheumatoid arthritis, and other similar disorders due to its ability to inhibit prostaglandin synthesis.
Used in Medical Treatment:
As a nonsteroidal anti-inflammatory drug, N-(4-chlorophenyl)ethanesulfonamide is used in medical treatment to alleviate symptoms of inflammation and pain. It is available in different forms such as tablets, capsules, and suspension for oral administration, providing flexibility in treatment options for patients.
It is crucial to administer N-(4-chlorophenyl)ethanesulfonamide under the guidance of a healthcare professional to monitor for potential side effects and drug interactions, ensuring the safe and effective use of this medication.

Upstream product

• 106-47-8 4-chloro-aniline 
• 594-44-5 Ethanesulfonyl chloride 

Downstream Products

• 23091-53-4 Ethanesulfonic acid (4-chloro-phenyl)-(1,1,2,2-tetrachloro-2-fluoro-ethylsulfanyl)-amide 

Relevant academic research and scientific papers

Ultrasound-assisted one-pot three-component synthesis of new isoxazolines bearing sulfonamides and their evaluation against hematological malignancies

In the present study, following a one-pot two-step protocol, we have synthesized novel sulfonamides-isoxazolines hybrids (3a-r) via a highly regioselective 1,3-dipolar cycloaddition. The present methodology capitalized on trichloroisocyanuric acid (TCCA) as a safe and ecological oxidant and chlorinating agent for the in-situ conversion of aldehydes to nitrile oxides in the presence of hydroxylamine hydrochloride, under ultrasound activation. These nitrile oxides could be engaged in 1,3-dipolar cycloaddition reactions with various alkene to afford the targeted sulfonamides-isoxazolines hybrids (3a-r). The latter were assessed for their antineoplastic activity against model leukemia cell lines (Chronic Myeloid Leukemia, K562 and Promyelocytic Leukemia, HL-60).

Cu-Mediated Synthesis of Indolines and Dihydroisoquinolinones through Arylperfluoroalkylation of Unactivated Alkenes

The copper-mediated fluroalkylation/cyclization of N-allyl anilines has been described using fluoroalkyl iodides as fluoroalkylation reagents for the first time. The reaction provides an efficient and direct access to 3-fluoroalkyl indolines in moderate to good yields with unactivated double bonds as the radical acceptor. This protocol combines a simple experimental procedure with low-costing fluoroalkylated sources and excellent functional group tolerance.

Amide compound for prevention and treatment of mental disorders

The present invention relates to an amide compound for prevention and treatment of mental disorders, which is shown as a formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof, a solvate thereof, a deuterated substance or a stereoisomer thereof. Wherein R1, R2, R3, R4, R5, Ar1, Ar2, p and q are as defined in the specification. The invention also relates to a preparation methodof the amide compound, a pharmaceutical composition and a pharmaceutical preparation containing the amide compound, and an application of the compound in preparation of a drug for prevention or treatment of mental disorders such as depression, depression and anxiety, and schizophrenia.

Synthesis and anti-cancer activities of new sulfonamides 4-substituted-triazolyl nucleosides

Nucleoside analogues are among the most known drugs commonly used in antiviral and anticancer chemotherapies. Among them, those featuring a five-membered ring nucleobase are of utmost interest such as the anti-cancer agent AICAR or the anti-viral drug ribavirin. Despite its low activity in vitro in different cell lines, AICAR is under clinical development for several pathologies, thanks to its original mode of action. Indeed, AICAR induced autophagy cell death and is able, following this mechanism, to circumvent resistance to apoptotic drugs including kinase inhibitors currently on the market. To improve the activity of AICAR, we report herein an efficient synthesis of new series of sulfonamide-4-substituted-1,2,3-triazolyl nucleosides using a Cu-catalyzed 1,3-dipolar cycloaddition. All these molecules have been fully characterized and evaluated against two aggressive tumor cell lines, RCC4 and MDA-MB-231. Among them, nucleoside analogue 5i belonging to the ribose series was found to be 19 to 66-fold more active than AICAR. Western blot analyses on RCC4 cells showed that 5i displayed an interesting mode of action by inducing both apoptosis and autophagy cell death, making therefore this class of molecules highly promising for further hit-to-lead optimization.